Growth Metrics

Voyager Therapeutics (VYGR) Cash from Investing Activities (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Cash from Investing Activities for 11 consecutive years, with $47.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 274.33% to $47.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125.4 million through Dec 2025, up 232.24% year-over-year, with the annual reading at $125.4 million for FY2025, 232.24% up from the prior year.
  • Cash from Investing Activities hit $47.4 million in Q4 2025 for Voyager Therapeutics, up from $34.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $64.4 million in Q3 2024 to a low of -$158.3 million in Q3 2023.
  • Historically, Cash from Investing Activities has averaged -$2.6 million across 5 years, with a median of $14.2 million in 2021.
  • Biggest five-year swings in Cash from Investing Activities: soared 1318.99% in 2021 and later crashed 762.93% in 2024.
  • Year by year, Cash from Investing Activities stood at -$5.5 million in 2021, then soared by 357.45% to $14.1 million in 2022, then skyrocketed by 90.75% to $26.8 million in 2023, then tumbled by 201.38% to -$27.2 million in 2024, then soared by 274.33% to $47.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for VYGR at $47.4 million in Q4 2025, $34.9 million in Q3 2025, and $1.9 million in Q2 2025.